Log In
Print
BCIQ
Print
Print this Print this
 

AZD3241

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionMyeloperoxidase (MPO) inhibitor
Molecular Target Myeloperoxidase (MPO)
Mechanism of ActionMyeloperoxide (MPO) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today